|
Liver carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Mono-polar spindle 1 (Mps1/TTK) represents a protein kinase reported to be vital for cell division processes and is generally regarded as an attractive target for the treatment of hepatocellular carcinoma, breast carcinoma, and colon cancer.
|
29925769 |
2018 |
|
Liver carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
In addition, the association of Mps1 expression with the overall survival of HCC patients was analysed.
|
28299790 |
2017 |
|
Liver carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
The dual-specificity protein kinase TTK, which is a key mitotic checkpoint regulator with links to p53 signaling, was further shown to be a promising overall prognostic marker for HCC in the large patient cohort.
|
24859455 |
2014 |
|
Liver carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
More importantly, TTK was observably up-regulated in 46 (86.8%) of 53 HCC specimens.
|
24905462 |
2014 |
|
Polycystic Ovary Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Sclerocystic Ovaries
|
0.300 |
Biomarker
|
disease |
CTD_human |
Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.
|
21411543 |
2011 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
AGO2, CDC20, CDCA5, MCM10, MYBL2, and TTK were identified as candidate biomarkers for further basic and clinical research on breast cancer based on co-expression analysis.
|
31280346 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High levels of Mps1 are found in various types of human malignancies, such as glioblastoma, osteosarcoma, hepatocellular carcinoma, and breast cancer.
|
30693152 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of ASPM, CDC20, and TTK Confer a Poorer Prognosis in Breast Cancer Identified by Gene Co-expression Network Analysis.
|
31106147 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Understanding the detailed resistance mechanism induced by Mps1 point mutations is therefore vital for the development of novel inhibitors against malignancies.
|
30693152 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of p-ERK and Mps1 in CRC with BRAF<sup>V600E</sup> was significantly higher compared with in CRC with BRAF<sup>WT</sup> (P<0.05), and their expression is associated with cancer classification, degree of differentiation and lymph node transfusion (P<0.05).
|
30854056 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several compounds targeting Mps1 have been developed and approved to begin clinical trials for advanced nonhaematologic malignancies treatments, including but not limited to triple negative breast cancer (TNBC) treatment.
|
31121430 |
2019 |
|
Mucopolysaccharidoses
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively reviewed the clinical ophthalmologic features and electrodiagnostic results of 50 Taiwanese patients with a diagnosis of MPS (34 males and 16 females; age range, 1.1-34.9 years; nine with MPS I, 17 with MPS II, 17 with MPS IV, and seven with MPS VI).
|
30848093 |
2019 |
|
Mucopolysaccharidoses
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 153 subjects enrolled in this study, 13 had a confirmative diagnosis of MPS (age range, 0.6 to 10.9 years-three with MPS I, four with MPS II, five with MPS IIIB, and one with MPS IVA).
|
31590383 |
2019 |
|
Mucopolysaccharidoses
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mucopolysaccharidosis type 1 (MPS-1), also known as Hurler's disease, is a congenital metabolic disorder caused by a mutation in the alpha-L-iduronidase (IDUA) gene, which results in the loss of lysosomal enzyme function for the degradation of glycosaminoglycans.
|
31065277 |
2019 |
|
Mucopolysaccharidoses
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background Mucopolysaccharidosis type 1 (MPS1) is a rare debilitating multisystem lysosomal disorder resulting due to the deficiency of α-L-iduronidase enzyme (IDUA), caused by recessive mutations in the IDUA gene.
|
31473686 |
2019 |
|
Mucopolysaccharidoses
|
0.100 |
Biomarker
|
disease |
BEFREE |
Corneal clouding, causing visual impairment, is seen in nearly all patients with Mucopolysaccharidosis type 1 (MPS-1).
|
31786241 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The possible effects of TTK on tumor growth and metastasis were measured in mice.
|
31607131 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of independent sample t test indicated that MCM10 and TTK were associated with tumor size, and that AGO2, CDC20, CDCA5, MCM10, and MYBL2 were overexpressed in lymph-node positive breast cancer.
|
31280346 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MPS-1 was correlated with advanced tumor stage, suggesting its association with CRC progression.
|
31506433 |
2019 |
|
Pfaundler-Hurler Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mucopolysaccharidosis type 1 (MPS-1), also known as Hurler's disease, is a congenital metabolic disorder caused by a mutation in the alpha-L-iduronidase (IDUA) gene, which results in the loss of lysosomal enzyme function for the degradation of glycosaminoglycans.
|
31065277 |
2019 |
|
Pfaundler-Hurler Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The estimated global incidence of MPS1 is 1:100,000 live births for the Hurler and 1:800,000 for the Scheie phenotypes.
|
31473686 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A previous study identified a novel gene, monopolar spindle protein kinase 1 (Mps1), a downstream target of BRAF<sup>V600E</sup> only, rather than of wild-type BRAF as well, which contributes to tumorigenesis in melanoma.
|
30854056 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In vivo experiments showed that TTK knockout inhibited tumorigenesis in mice.
|
31605696 |
2019 |